193 related articles for article (PubMed ID: 33616889)
1. Naxitamab: First Approval.
Markham A
Drugs; 2021 Feb; 81(2):291-296. PubMed ID: 33616889
[TBL] [Abstract][Full Text] [Related]
2. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma.
Slatnick LR; Jimeno A; Gore L; Macy ME
Drugs Today (Barc); 2021 Nov; 57(11):677-688. PubMed ID: 34821881
[TBL] [Abstract][Full Text] [Related]
3. How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain.
Castañeda A; Gorostegui M; Miralles SL; Chamizo A; Patiño SC; Flores MA; Garraus M; Lazaro JJ; Santa-Maria V; Varo A; Muñoz JP; Mora J
ESMO Open; 2022 Apr; 7(2):100462. PubMed ID: 35397431
[TBL] [Abstract][Full Text] [Related]
4. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.
Mora J; Castañeda A; Gorostegui M; Santa-María V; Garraus M; Muñoz JP; Varo A; Perez-Jaume S; Mañe S
Pediatr Blood Cancer; 2021 Oct; 68(10):e29121. PubMed ID: 34022112
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital.
Trovillion EM; Michael M; Jordan CC; Brown L; Phillips K; Oesterheld J; Saulnier-Sholler G
Cancer Med; 2024 Feb; 13(3):e7045. PubMed ID: 38396377
[TBL] [Abstract][Full Text] [Related]
6. Dinutuximab: first global approval.
Dhillon S
Drugs; 2015 May; 75(8):923-7. PubMed ID: 25940913
[TBL] [Abstract][Full Text] [Related]
7. Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events.
Mora J; Chan GC; Morgenstern DA; Nysom K; Bear MK; Tornøe K; Kushner BH
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1627. PubMed ID: 35579862
[TBL] [Abstract][Full Text] [Related]
8. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
[TBL] [Abstract][Full Text] [Related]
9. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
10. Partial Response to Naxitamab for Brain Metastasis in Neuroblastoma.
Onyeukwu C; Williams A; Seyboth B; Muñoz L; Scaria G; Kent P
J Pediatr Hematol Oncol; 2024 Mar; 46(2):e188-e190. PubMed ID: 38189408
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
12. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
Muñoz JP; Larrosa C; Chamorro S; Perez-Jaume S; Simao M; Sanchez-Sierra N; Varo A; Gorostegui M; Castañeda A; Garraus M; Lopez-Miralles S; Mora J
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835531
[TBL] [Abstract][Full Text] [Related]
13. Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma.
Cabral J; Fernandez EI; Toy B; Secola R
Paediatr Drugs; 2023 Jan; 25(1):13-25. PubMed ID: 36434427
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with anti-G
Kushner BH; Modak S; Kramer K; Basu EM; Iglesias-Cardenas F; Roberts SS; Cheung NV
Int J Cancer; 2023 Jan; 152(2):259-266. PubMed ID: 35913764
[TBL] [Abstract][Full Text] [Related]
15. Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report.
Mora J; Castañeda A; Gorostegui M; Varo A; Perez-Jaume S; Simao M; Muñoz JP; Garraus M; Larrosa C; Salvador N; Lavarino C; Krauel L; Mañe S
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174002
[TBL] [Abstract][Full Text] [Related]
16. Isatuximab: First Approval.
Dhillon S
Drugs; 2020 Jun; 80(9):905-912. PubMed ID: 32347476
[TBL] [Abstract][Full Text] [Related]
17. A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors.
Bishop MW; Hutson PR; Hank JA; Sondel PM; Furman WL; Meagher MM; Navid F; Santana VM
MAbs; 2020; 12(1):1773751. PubMed ID: 32643524
[TBL] [Abstract][Full Text] [Related]
18. Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
Yankelevich M; Thakur A; Modak S; Chu R; Taub J; Martin A; Schalk D; Schienshang A; Whitaker S; Rea K; Lee DW; Liu Q; Shields AF; Cheung NV; Lum LG
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519053
[TBL] [Abstract][Full Text] [Related]
19. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
McGinty L; Kolesar J
Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]